UBS Group’s PAVmed Inc. Series Z Warrant PAVMZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-3,205
Closed -$20 11146
2025
Q1
$20 Sell
3,205
-4,503
-58% -$41 ﹤0.01% 10093
2024
Q4
$77 Sell
7,708
-749
-9% -$15 ﹤0.01% 9674
2024
Q3
$178 Buy
8,457
+7,857
+1,310% +$240 ﹤0.01% 9090
2024
Q2
$12 Sell
600
-80
-12% -$3 ﹤0.01% 9339
2024
Q1
$24 Buy
680
+80
+13% +$5 ﹤0.01% 9017
2023
Q4
$66 Hold
600
﹤0.01% 8963
2023
Q3
$72 Sell
600
-325
-35% -$39 ﹤0.01% 8946
2023
Q2
$148 Sell
925
-245
-21% -$32 ﹤0.01% 8447
2023
Q1
$176 Sell
1,170
-10,915
-90% -$2.15K ﹤0.01% 9154
2022
Q4
$2.66K Buy
12,085
+10,333
+590% +$4.28K ﹤0.01% 9645
2022
Q3
$1K Sell
1,752
-8,050
-82% -$5.47K ﹤0.01% 10072
2022
Q2
$5K Buy
9,802
+4,859
+98% +$3.06K ﹤0.01% 8953
2022
Q1
$4K Buy
4,943
+3,808
+336% +$3.92K ﹤0.01% 9335
2021
Q4
$2K Sell
1,135
-1,942
-63% -$6.79K ﹤0.01% 9847
2021
Q3
$21K Sell
3,077
-2,757
-47% -$14.9K ﹤0.01% 7122
2021
Q2
$28K Buy
5,834
+4,049
+227% +$15K ﹤0.01% 7012
2021
Q1
$5K Buy
+1,785
New +$3.6K ﹤0.01% 8344
2020
Q2
Sell
-490
Closed 8445
2020
Q1
$0 Buy
490
+287
+141% +$229 ﹤0.01% 8514
2019
Q4
$0 Sell
203
-14,097
-99% -$4.42K ﹤0.01% 8473
2019
Q3
$5K Buy
14,300
+1,100
+8% +$375 ﹤0.01% 7500
2019
Q2
$6K Buy
13,200
+100
+0.8% +$40 ﹤0.01% 7332
2019
Q1
$5K Hold
13,100
﹤0.01% 7195
2018
Q4
$4K Buy
13,100
+8,700
+198% +$2.92K ﹤0.01% 7651
2018
Q3
$2K Sell
4,400
-5,478
-55% -$2.72K ﹤0.01% 7761
2018
Q2
$3K Buy
+9,878
New +$4.86K ﹤0.01% 7661

UBS Group's PAVMZ Position: Q2 2025 in Review

UBS Group sold out of PAVmed Inc. Series Z Warrant (PAVMZ) in Q2 2025, closing a stake of 3,205 shares — an estimated $20 sold.

UBS Group first reported a position in PAVMZ in Q2 2018 and held it in 25 quarters. The position peaked at $28K in Q2 2021. 0 funds tracked by Wall St. Rank hold PAVMZ as of Q2 2025.

  • UBS Group reported no remaining PAVmed Inc. Series Z Warrant position as of Q2 2025 after selling out during the quarter.
  • UBS Group sold 3,205 PAVmed Inc. Series Z Warrant shares in Q2 2025, an estimated $20.
  • UBS Group first reported a position in PAVmed Inc. Series Z Warrant in Q2 2018 and held it in 25 quarters.
  • UBS Group's PAVmed Inc. Series Z Warrant position peaked at $28K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held PAVmed Inc. Series Z Warrant as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.